{"success":true,"data":{"pressRelease":{"id":"164775","rtpr_id":"nPNAxl9bMa-20261008","ticker":"TLX","exchange":"ASX","all_tickers":["TLX"],"title":"Telix to Host Capital Markets Day in Melbourne on November 4, 2026","author":"PR Newswire","published_at":"2026-10-08T20:00:01.069Z","article_body":"Telix to Host Capital Markets Day in Melbourne on November 4, 2026\nPR Newswire\n\nMELBOURNE, Australia and INDIANAPOLIS, Oct. 9, 2026\n\nMELBOURNE, Australia and INDIANAPOLIS, Oct. 9, 2026 /PRNewswire/ -- Telix\nPharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, \"Telix\") today announced that\nit will host a Capital Markets Day in Melbourne, Australia, on Wednesday,\nNovember 4, 2026, from 9:00 a.m. to 12:30 p.m. (AEDT).\n\n\nInstitutional investors and analysts are invited to attend the in-person\nevent, which will provide an update on Telix's commercial portfolio,\nlate-stage pipeline and strategic growth opportunities. Members of the Telix\nleadership team will present at the event, which will also feature key opinion\nleaders who will provide their perspectives on Telix's theranostic programs.\n\nAdvance registration is required for in-person attendance. To register your\ninterest please contact: charlene.jaw@telixpharma.com or\nannie.kasparian@telixpharma.com.\n\nThe event will be webcast live and available via the Investor Relations\nsection of the Telix website.\n\nAbout Telix Pharmaceuticals Limited\n\nTelix Pharmaceuticals (ASX: TLX, NASDAQ: TLX) is a commercial-stage global\nradiopharmaceutical company, advancing targeted theranostics to improve\noutcomes for people with cancer across the patient journey. Theranostics pairs\na precision diagnostic with a targeted therapy to both diagnose and treat\ndisease. \n\nTelix's commercial franchise is anchored by its precision diagnostics\nportfolio: Illuccix® (kit for the preparation of gallium-68 gozetotide\ninjection), commercially available in 22 countries including the U.S., and\nGozellix® (kit for the preparation of gallium-68 gozetotide injection),\napproved by the U.S. Food and Drug Administration (FDA) for prostate\nimaging, and Pixclara® (floretyrosine F 18) approved by the FDA for glioma\nimaging. The Company's late-stage therapeutic pipeline includes three\ninvestigational assets in pivotal-stage trials: TLX591-Tx (lutetium-177\n((177)Lu) rosopatamab tetraxetan) in prostate cancer, TLX101-Tx (iodofalan\n(131)I) in recurrent glioblastoma, and TLX250-Tx (lutetium\n((177)Lu) girentuximab tetraxetan) in kidney\ncancer, additionally complemented by a deep pipeline of next generation\ncandidates.\n\nTelix is headquartered in Melbourne, Australia, with operations across North\nAmerica, Europe, Latin America and Asia-Pacific. For more information, visit\nwww.telixpharma.com or follow Telix on LinkedIn\n(https://www.linkedin.com/company/telixpharma/),X (https://x.com/TelixPharma)\nand Facebook (https://www.facebook.com/TelixPharma).\n\n Investor Relations Annie Kasparian   Charlene Jaw                   \n annie.kasparian@telixpharma.com      charlene.jaw@telixpharma.com   \n\nLegal Notices\n\nCautionary Statement Regarding Forward-Looking Statements.  \n \n\nYou should read this announcement together with our risk factors, as disclosed\nin our most recently filed reports with the Australian Securities Exchange\n(ASX), U.S. Securities and Exchange Commission (SEC), including our Annual\nReport on Form 20-F filed with the SEC, or on our website.\n\nThe information contained in this announcement is not intended to be an offer\nfor subscription, invitation or recommendation with respect to securities of\nTelix Pharmaceuticals Limited (Telix) in any jurisdiction, including the\nUnited States. The information and opinions contained in this announcement are\nsubject to change without notification.  To the maximum extent permitted by\nlaw, Telix disclaims any obligation or undertaking to update or revise any\ninformation or opinions contained in this announcement, including any\nforward-looking statements (as referred to below), whether as a result of new\ninformation, future developments, a change in expectations or assumptions, or\notherwise. No representation or warranty, express or implied, is made in\nrelation to the accuracy or completeness of the information contained or\nopinions expressed in the course of this announcement.\n\nThis announcement may contain forward-looking statements, including within the\nmeaning of the U.S. Private Securities Litigation Reform Act of 1995, that\nrelate to anticipated future events, financial performance, plans, strategies\nor business developments. Forward-looking statements can generally be\nidentified by the use of words such as \"may\", \"expect\", \"intend\", \"plan\",\n\"estimate\", \"anticipate\", \"believe\", \"outlook\", \"forecast\" and \"guidance\", or\nthe negative of these words or other similar terms or expressions.\nForward-looking statements involve known and unknown risks, uncertainties and\nother factors that may cause our actual results, levels of activity,\nperformance or achievements to differ materially from any future results,\nlevels of activity, performance or achievements expressed or implied by these\nforward-looking statements. Forward-looking statements are based on Telix's\ngood-faith assumptions as to the financial, market, regulatory and other risks\nand considerations that exist and affect Telix's business and operations in\nthe future and there can be no assurance that any of the assumptions will\nprove to be correct. In the context of Telix's business, forward-looking\nstatements may include, but are not limited to, statements about: the\ninitiation, timing, progress, completion and results of Telix's preclinical\nand clinical trials, and Telix's research and development programs; Telix's\nability to advance product candidates into, enroll and successfully complete,\nclinical studies, including multi-national clinical trials; the timing or\nlikelihood of regulatory filings and approvals for Telix's product candidates,\nmanufacturing activities and product marketing activities; Telix's sales,\nmarketing and distribution and manufacturing capabilities and strategies; the\ncommercialization of Telix's product candidates, if or when they have been\napproved; Telix's ability to obtain an adequate supply of raw materials at\nreasonable costs for its products and product candidates; estimates of Telix's\nexpenses, future revenues and capital requirements; Telix's financial\nperformance; developments relating to Telix's competitors and industry; the\nanticipated impact of U.S. and foreign tariffs and other macroeconomic\nconditions on Telix's business, including as a result of war or other\ngeopolitical conflicts; and the pricing and reimbursement of Telix's product\ncandidates, if and after they have been approved. Telix's actual results,\nperformance or achievements may be materially different from those which may\nbe expressed or implied by such statements, and the differences may be\nadverse. Accordingly, you should not place undue reliance on these\nforward-looking statements.\n\nTrademarks and Trade Names. All trademarks and trade names referenced in this\npress release are the property of Telix Pharmaceuticals Limited (Telix) or,\nwhere applicable, the property of their respective owners. For convenience,\ntrademarks and trade names may appear without the ® or ™ symbols. Such\nomissions are not intended to indicate any waiver of rights by Telix or the\nrespective owners. Trademark registration status may vary from country to\ncountry. Telix does not intend the use or display of any third-party\ntrademarks or trade names to imply any affiliation with, endorsement by, or\nsponsorship from those third parties.\n\n©2026 Telix Pharmaceuticals Limited. All rights reserved.\n\nView original content to download\nmultimedia:https://www.prnewswire.com/apac/news-releases/telix-to-host-capital-markets-day-in-melbourne-on-november-4-2026-302902277.html\n\nSOURCE Telix Pharmaceuticals Limited\n\n\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1385889/Telix-Main-Logo-Logo.jpg?id=OA2994519\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPNAxl9bMa-20261008","title":"Telix to Host Capital Markets Day in Melbourne on November 4, 2026","author":"PR Newswire","ticker":"TLX","created":"2026-10-08T20:00:01.069Z","tickers":["TLX"],"exchange":"ASX","article_body":"Telix to Host Capital Markets Day in Melbourne on November 4, 2026\nPR Newswire\n\nMELBOURNE, Australia and INDIANAPOLIS, Oct. 9, 2026\n\nMELBOURNE, Australia and INDIANAPOLIS, Oct. 9, 2026 /PRNewswire/ -- Telix\nPharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, \"Telix\") today announced that\nit will host a Capital Markets Day in Melbourne, Australia, on Wednesday,\nNovember 4, 2026, from 9:00 a.m. to 12:30 p.m. (AEDT).\n\n\nInstitutional investors and analysts are invited to attend the in-person\nevent, which will provide an update on Telix's commercial portfolio,\nlate-stage pipeline and strategic growth opportunities. Members of the Telix\nleadership team will present at the event, which will also feature key opinion\nleaders who will provide their perspectives on Telix's theranostic programs.\n\nAdvance registration is required for in-person attendance. To register your\ninterest please contact: charlene.jaw@telixpharma.com or\nannie.kasparian@telixpharma.com.\n\nThe event will be webcast live and available via the Investor Relations\nsection of the Telix website.\n\nAbout Telix Pharmaceuticals Limited\n\nTelix Pharmaceuticals (ASX: TLX, NASDAQ: TLX) is a commercial-stage global\nradiopharmaceutical company, advancing targeted theranostics to improve\noutcomes for people with cancer across the patient journey. Theranostics pairs\na precision diagnostic with a targeted therapy to both diagnose and treat\ndisease. \n\nTelix's commercial franchise is anchored by its precision diagnostics\nportfolio: Illuccix® (kit for the preparation of gallium-68 gozetotide\ninjection), commercially available in 22 countries including the U.S., and\nGozellix® (kit for the preparation of gallium-68 gozetotide injection),\napproved by the U.S. Food and Drug Administration (FDA) for prostate\nimaging, and Pixclara® (floretyrosine F 18) approved by the FDA for glioma\nimaging. The Company's late-stage therapeutic pipeline includes three\ninvestigational assets in pivotal-stage trials: TLX591-Tx (lutetium-177\n((177)Lu) rosopatamab tetraxetan) in prostate cancer, TLX101-Tx (iodofalan\n(131)I) in recurrent glioblastoma, and TLX250-Tx (lutetium\n((177)Lu) girentuximab tetraxetan) in kidney\ncancer, additionally complemented by a deep pipeline of next generation\ncandidates.\n\nTelix is headquartered in Melbourne, Australia, with operations across North\nAmerica, Europe, Latin America and Asia-Pacific. For more information, visit\nwww.telixpharma.com or follow Telix on LinkedIn\n(https://www.linkedin.com/company/telixpharma/),X (https://x.com/TelixPharma)\nand Facebook (https://www.facebook.com/TelixPharma).\n\n Investor Relations Annie Kasparian   Charlene Jaw                   \n annie.kasparian@telixpharma.com      charlene.jaw@telixpharma.com   \n\nLegal Notices\n\nCautionary Statement Regarding Forward-Looking Statements.  \n \n\nYou should read this announcement together with our risk factors, as disclosed\nin our most recently filed reports with the Australian Securities Exchange\n(ASX), U.S. Securities and Exchange Commission (SEC), including our Annual\nReport on Form 20-F filed with the SEC, or on our website.\n\nThe information contained in this announcement is not intended to be an offer\nfor subscription, invitation or recommendation with respect to securities of\nTelix Pharmaceuticals Limited (Telix) in any jurisdiction, including the\nUnited States. The information and opinions contained in this announcement are\nsubject to change without notification.  To the maximum extent permitted by\nlaw, Telix disclaims any obligation or undertaking to update or revise any\ninformation or opinions contained in this announcement, including any\nforward-looking statements (as referred to below), whether as a result of new\ninformation, future developments, a change in expectations or assumptions, or\notherwise. No representation or warranty, express or implied, is made in\nrelation to the accuracy or completeness of the information contained or\nopinions expressed in the course of this announcement.\n\nThis announcement may contain forward-looking statements, including within the\nmeaning of the U.S. Private Securities Litigation Reform Act of 1995, that\nrelate to anticipated future events, financial performance, plans, strategies\nor business developments. Forward-looking statements can generally be\nidentified by the use of words such as \"may\", \"expect\", \"intend\", \"plan\",\n\"estimate\", \"anticipate\", \"believe\", \"outlook\", \"forecast\" and \"guidance\", or\nthe negative of these words or other similar terms or expressions.\nForward-looking statements involve known and unknown risks, uncertainties and\nother factors that may cause our actual results, levels of activity,\nperformance or achievements to differ materially from any future results,\nlevels of activity, performance or achievements expressed or implied by these\nforward-looking statements. Forward-looking statements are based on Telix's\ngood-faith assumptions as to the financial, market, regulatory and other risks\nand considerations that exist and affect Telix's business and operations in\nthe future and there can be no assurance that any of the assumptions will\nprove to be correct. In the context of Telix's business, forward-looking\nstatements may include, but are not limited to, statements about: the\ninitiation, timing, progress, completion and results of Telix's preclinical\nand clinical trials, and Telix's research and development programs; Telix's\nability to advance product candidates into, enroll and successfully complete,\nclinical studies, including multi-national clinical trials; the timing or\nlikelihood of regulatory filings and approvals for Telix's product candidates,\nmanufacturing activities and product marketing activities; Telix's sales,\nmarketing and distribution and manufacturing capabilities and strategies; the\ncommercialization of Telix's product candidates, if or when they have been\napproved; Telix's ability to obtain an adequate supply of raw materials at\nreasonable costs for its products and product candidates; estimates of Telix's\nexpenses, future revenues and capital requirements; Telix's financial\nperformance; developments relating to Telix's competitors and industry; the\nanticipated impact of U.S. and foreign tariffs and other macroeconomic\nconditions on Telix's business, including as a result of war or other\ngeopolitical conflicts; and the pricing and reimbursement of Telix's product\ncandidates, if and after they have been approved. Telix's actual results,\nperformance or achievements may be materially different from those which may\nbe expressed or implied by such statements, and the differences may be\nadverse. Accordingly, you should not place undue reliance on these\nforward-looking statements.\n\nTrademarks and Trade Names. All trademarks and trade names referenced in this\npress release are the property of Telix Pharmaceuticals Limited (Telix) or,\nwhere applicable, the property of their respective owners. For convenience,\ntrademarks and trade names may appear without the ® or ™ symbols. Such\nomissions are not intended to indicate any waiver of rights by Telix or the\nrespective owners. Trademark registration status may vary from country to\ncountry. Telix does not intend the use or display of any third-party\ntrademarks or trade names to imply any affiliation with, endorsement by, or\nsponsorship from those third parties.\n\n©2026 Telix Pharmaceuticals Limited. All rights reserved.\n\nView original content to download\nmultimedia:https://www.prnewswire.com/apac/news-releases/telix-to-host-capital-markets-day-in-melbourne-on-november-4-2026-302902277.html\n\nSOURCE Telix Pharmaceuticals Limited\n\n\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1385889/Telix-Main-Logo-Logo.jpg?id=OA2994519\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-10-08T20:00:01.105059193Z","server_sent_at_ms":1791489601105},"received_at":"2026-10-08T20:00:01.155Z","source_url":null},"analysis":{"id":"153177","press_release_id":"164775","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"Telix Pharmaceuticals will host a Capital Markets Day in Melbourne on November 4, 2026, from 9:00 a.m. to 12:30 p.m. AEDT.\n\nThe event will cover the commercial portfolio, late-stage pipeline, and strategic growth opportunities, with leadership and key opinion leaders presenting; it will be webcast live via the investor relations site.\n\nThis is a scheduling notice only -- no financial results or guidance are included; the release reiterates products such as Illuccix, Gozellix, Pixclara, and three pivotal-stage therapeutic programs.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Calendar item: Telix Capital Markets Day November 4 -- set reminder for pipeline updates."},"keyFigures":{},"namedEntities":{"people":[],"products":["Illuccix","Gozellix","Pixclara","TLX591-Tx","TLX101-Tx","TLX250-Tx"],"companies":[{"name":"Telix Pharmaceuticals Limited","ticker":"TLX","relationship":"filer"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Boilerplate event-scheduling notice for a Capital Markets Day; no results, guidance, or transactional content disclosed."},"tickerRelevance":{"others":[],"primary":"TLX"},"globalImportance":10,"audienceRelevance":25,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"mid-cap-biotech","eventGravity":"event-scheduling-notice","issuerAuthored":true}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Telix Pharmaceuticals will host a Capital Markets Day in Melbourne on November 4, 2026, from 9:00 a.m. to 12:30 p.m. AEDT.\n\nThe event will cover the commercial portfolio, late-stage pipeline, and strategic growth opportunities, with leadership and key opinion leaders presenting; it will be webcast live via the investor relations site.\n\nThis is a scheduling notice only -- no financial results or guidance are included; the release reiterates products such as Illuccix, Gozellix, Pixclara, and three pivotal-stage therapeutic programs.","key_figures":{},"named_entities":{"people":[],"products":["Illuccix","Gozellix","Pixclara","TLX591-Tx","TLX101-Tx","TLX250-Tx"],"companies":[{"name":"Telix Pharmaceuticals Limited","ticker":"TLX","relationship":"filer"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-08T20:00:04.829Z","global_importance":10,"audience_relevance":25,"importance_components":{"tickerTier":"mid-cap-biotech","eventGravity":"event-scheduling-notice","issuerAuthored":true}},"durationMs":3644,"modelName":"glm-5.3-flashx"}}